This is a promotional email for UK Healthcare Professionals, sent on behalf of Takeda UK Limited.
Prescribing information and adverse event reporting information can be found here and at the bottom of this email.
Problems viewing this email? View it in your browser |
|
|
| ▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Adverse events should reported. Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Takeda at AE.GBR-IRL@takeda.com |
|
|
|
| CINRYZE is indicated for:1,2
|
| • |
Treatment and pre-procedure prevention of angioedema attacks in adults, adolescents and children (2-years old and above) with HAE |
| • |
Routine prevention of angioedema attacks in adults, adolescents and children (6-years old and above) with severe and recurrent attacks of HAE, who are intolerant to or insufficiently protected by oral prevention treatments, or patients who are inadequately managed with repeated acute treatment |
|
| For patients with hereditary angioedema (HAE), consider CINRYZE |
The C1-esterase inhibitor of choice
for the NHS*3 |
|
|
|
|
| CINRYZE is awarded Rank 1 C1-esterase inhibitor in the NHS National Tender Framework for the acute management of HAE, based on price, ease of use and security of supply.3 |
|
|
|
|
| As the NHS’s C1-esterase inhibitor of choice* for HAE, CINRYZE benefits from: |
 |
The broadest range of indications, as the only C1-esterase inhibitor in the UK approved for long-term prophylaxis in adult, adolescent and paediatric (≥6 years) patients1,2,4,5 |
|
 |
A proven efficacy profile, demonstrating: |
|
| • |
A 93.7% reduction in HAE attack frequency†6 |
|
| - |
Open-label extension study of patients aged 3-82 years (n=146)6 |
|
| • |
A 32% reduction in attack severity vs placebo‡1,2,7 |
|
| - |
Placebo-controlled, 12-week, crossover study in patients aged ≥6 years (n=22)7 |
|
| • |
A 72% reduction in acute attacks requiring treatment in paediatric patients§8 |
|
| - |
Randomised, single-blind, crossover trial in patients aged 6–11 years (n=12)8 |
|
|
|
 |
A well-tolerated safety profile backed by over 10 years of clinical experience and >6,800 patient years¶1,2,6,9 |
|
 |
Ease of dosing, with no calculations of dose/kg required1,2 |
|
 |
An optional fully-funded, patient-centred homecare service offered as part of a package deal |
|
| Explore CINRYZE, and discuss how its current HAE tender positioning could benefit your patients and practice |
Please select YES if you would like to speak
with a Takeda UK Limited representative. |
|
(By selecting YES, you are confirming you are happy for your contact details to be disclosed by Data4NHS with
Takeda UK Limited solely to fulfil this request and to be retained for no longer than necessary for this purpose) |
|
| Footnotes |
*Based on price, ease of use and supply.1
†An open-label extension study involving adult, adolescent & paediatric patients aged between 3-82 years. PRIMARY EP: Number of angioedema attacks. RESULTS: Median of 0.19 attacks/month (IQR, 0.00–0.64) on CINRYZE 1,000 IU every 3-7 days vs. 3 attacks/month (IQR, 2–4); n=146; treated for up to 2.6 years.6
‡A placebo-controlled, 12-week, crossover study in 22 patients aged 6-years or older. SECONDARY EP = average severity of attacks. Results: 1.3±0.85 at baseline.8
§A Phase 3 trial which included 12 paediatric patients aged 6-11 years. EP = number of attacks recieving acute treatment. Results: 0.65 on CINRYZE 500 IU vs. 2.29.8
¶Cumulative person-years of treatment between October 2008 and June 2016.9 |
|
| Abbreviations |
AR; Adverse Reactions, EP; endpoint; HAE; Hereditary Angioedema, IQR; Interquartile Range, IU; International Unit, IV; Intravenous,
U; Unit. |
|
| References |
| 1. |
CINRYZE®▼ (C1-esterase inhibitor [human]) Great Britain Summary of Product Characteristics. |
| 2. |
CINRYZE®▼ (C1-esterase inhibitor [human]) Northern Ireland Summary of Product Characteristics. |
| 3. |
National Health Service. Document No. 03 - Framework Agreement and Terms and Conditions (CM/PHS/19/5583). Available at:https://atamis-1928.my.salesforce.com/sfc/p/#0O000000rwim/a/8d000000IwUB/eswUdx.fNY3sE8ndOUMY36Ju0xD56JNSvqa1YASOxxg. [Accessed December 2023]. |
| 4. |
Berinert UK Summary of Product Characteristics. |
| 5. |
Ruconest UK Summary of Product Characteristics. |
| 6. |
Zuraw BL et al. Am J Med. 2012;125(9):931e1–7. |
| 7. |
Zuraw BL et al. N Engl J Med. 2010;363(6):513–22. |
| 8. |
Aygoren-Piirsun E. et al. Pediatr Allergy lmmunol. 2019;30(5):553–61. |
| 9. |
Shire. Data on File: SHP616-004. |
|
| Click here for CINRYZE Prescribing Information |
Job code: C-APROM/GB/HAE/0122
Date of preparation: December 2023 |
|
|
©2023 Takeda UK Limited. All rights reserved. TAKHZYRO® is a registered trademark of Dyax Corp.
Takeda® and the Takeda Logo® are registered trademarks of Takeda Pharmaceutical Company Limited.
Takeda UK Limited, 1 Kingdom Street, London, W2 6BD, United Kingdom. |
|
|
This email has been forwarded to you by Data4NHS on behalf of Takeda UK Limited.
Manage your Data4NHS profile by submitting your changes HERE.
View our privacy policy HERE.
UNSUBSCRIBE |
|
